GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xlife Sciences AG (XSWX:XLS) » Definitions » Asset Turnover

Xlife Sciences AG (XSWX:XLS) Asset Turnover : 0.00 (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Xlife Sciences AG Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Xlife Sciences AG's Revenue for the six months ended in Jun. 2024 was CHF0.35 Mil. Xlife Sciences AG's Total Assets for the quarter that ended in Jun. 2024 was CHF510.93 Mil. Therefore, Xlife Sciences AG's Asset Turnover for the quarter that ended in Jun. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Xlife Sciences AG's annualized ROE % for the quarter that ended in Jun. 2024 was 0.35%. It is also linked to ROA % through Du Pont Formula. Xlife Sciences AG's annualized ROA % for the quarter that ended in Jun. 2024 was 0.19%.


Xlife Sciences AG Asset Turnover Historical Data

The historical data trend for Xlife Sciences AG's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xlife Sciences AG Asset Turnover Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial - - - - -

Xlife Sciences AG Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Xlife Sciences AG's Asset Turnover

For the Biotechnology subindustry, Xlife Sciences AG's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xlife Sciences AG's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Xlife Sciences AG's Asset Turnover falls into.



Xlife Sciences AG Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Xlife Sciences AG's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0.988/( (490.23+511.994)/ 2 )
=0.988/501.112
=0.00

Xlife Sciences AG's Asset Turnover for the quarter that ended in Jun. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Jun. 2024 ))/ count )
=0.35/( (511.994+509.862)/ 2 )
=0.35/510.928
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Xlife Sciences AG  (XSWX:XLS) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Xlife Sciences AG's annulized ROE % for the quarter that ended in Jun. 2024 is

ROE %**(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=0.946/270.499
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(0.946 / 0.7)*(0.7 / 510.928)*(510.928/ 270.499)
=Net Margin %*Asset Turnover*Equity Multiplier
=135.14 %*0.0014*1.8888
=ROA %*Equity Multiplier
=0.19 %*1.8888
=0.35 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2024) net income data. The Revenue data used here is two times the semi-annual (Jun. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Xlife Sciences AG's annulized ROA % for the quarter that ended in Jun. 2024 is

ROA %(Q: Jun. 2024 )
=Net Income/Total Assets
=0.946/510.928
=(Net Income / Revenue)*(Revenue / Total Assets)
=(0.946 / 0.7)*(0.7 / 510.928)
=Net Margin %*Asset Turnover
=135.14 %*0.0014
=0.19 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2024) net income data. The Revenue data used here is two times the semi-annual (Jun. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Xlife Sciences AG Asset Turnover Related Terms

Thank you for viewing the detailed overview of Xlife Sciences AG's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Xlife Sciences AG Business Description

Traded in Other Exchanges
Address
Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial intelligence/digital medicine.

Xlife Sciences AG Headlines

No Headlines